Jackson and colleagues' (1) conclusion that nurse practitioners (NPs) and physician assistants (PAs) can effectively manage a chronic condition, such as diabetes mellitus, in a controlled setting is reasonable. However, Peters' editorial (2) makes assumptions that are not supported by evidence. The editorialist states that NPs and PAs are competent primary care providers. Although Jackson and colleagues did not find any clinically significant difference in intermediate diabetes outcomes among patients treated by physicians, NPs, or PAs, their study was confined to a closed, team-based system (U.S. Department of Veterans Affairs [VA] primary care facilities) and concerned a single chronic disease where "cookie-cutter" medicine might work. Primary care physicians, such as internists and family practitioners, are trained to diagnose and treat several other complex conditions.
such as internists and family practitioners, are trained to diagnose and treat several other complex conditions.
The educational gap between physicians and other providers is important in this context. Shaffer and associates (3) state that an average family medicine physician receives 21 000 hours of training, whereas a typical NP receives 2300 to 5300 hours. They also note that physician training involves management responsibilities and decreasing levels of supervision, whereas NP training is mostly observational. The diagnostic and management challenges that primary care physicians face are immense, and preparing for them requires extensive clinical exposure.
Nurse practitioners and PAs are becoming popular in the United States for many reasons, with a shortage of primary care physicians at the top of the list. New medical graduates with heavy debt burdens are avoiding primary care specialties and opting for higher-paying specialties or positions as hospitalists. Payors and employers also may prefer to hire NPs and PAs because they cost less. An increasing number of patients are using NPs and PAs as their primary providers, but they cannot replace physicians. I believe that NPs and PAs have a robust role in the team approach to primary care. Extrapolating that role to the position of a full-fledged primary care provider is not scientific in the absence of solid data.
P. Dileep Kumar, MD East Michigan Hospitalists Port Huron, Michigan
Disclosures: Disclosures can be viewed at www.acponline.org /authors/icmje/ConflictOfInterestForms.do?msNum=L19-0199. doi:10.7326/L19-0199 TO THE EDITOR: I do not necessarily disagree with the conclusions of Jackson and colleagues' article (1) or Peters' accompanying editorial (2) . However, I believe that Jackson and colleagues' cohort study is subject to a characteristic of VA populations that is frequently ignored: A substantial portion of VA patients take advantage of VA assistance for medications and supplies but receive medical care outside of the VA system. In my 5 years of working as a VA clinic physician (between 2007 and 2012), few diabetic patients I saw received supervision for their diabetes solely from VA sources; this was particularly true of patients whom I saw infrequently. The VA medical system has many characteristics that influence content and accessibility of health records, selection of medication, and testing and availability of services and equipment. These factors are not necessarily bad, but I believe that dissimilar circumstances in general need to be considered and often specifically addressed when interpreting any cohort study involving the VA or any other population. 
James Grote, MD

IN RESPONSE:
We appreciate these comments and that readers agreed with our conclusions within the scope of the specific research. We sought to take advantage of the size of the VA health care system, the ability to use electronic health records to determine which providers saw patients, and the extensive access to the results of laboratory studies and vital sign measurements and to patient-level data that allowed for advanced statistical analyses. When combined with evidence from other investigators (including trials and observational studies) (1-4), our article offers additional support for the role of NPs and PAs as primary care providers for patients with diabetes. We do not suggest that NPs and PAs should replace physicians. Rather, our article is only 1 piece of the puzzle that must continue to be filled in with additional research.
In an era of increased team-based care, we need more health services research on how best to organize these teams and use the skills of team members. Providers-including physicians, NPs, and PAs-have always had to make decisions about when to involve other clinicians in patient care. For example, primary care providers may refer patients to specialist colleagues and PAs and NPs may consult physicians.
Introducing such concepts as the patient-centered medical home provides opportunities to refine the various possible team-based structures and roles (5) . Dr. Kumar correctly notes that physicians, NPs, and PAs receive different training. We hope that funding agencies continue to appreciate the need to study how these differences (including those involving lengths of training in formal programs) may affect outcomes, specific clinical roles, and how to optimally support all providers in their early career.
We agree with Dr. Grote that there is a need to continue expanding research on how best to use teams and individual clinicians (including PAs and NPs) in a wide variety of settings. The VA has long been an excellent place to study innovative care structures. However, like every health care system in the United States, it has unique aspects. Only through continuing to expand the body of literature on care teams and the roles of physicians, NPs, and PAs will we be able to fill in more of the puzzle pieces on how best to structure care to serve patients.
Long-Term Protection After Fractional-Dose Yellow Fever Vaccination
TO THE EDITOR:
We read Roukens and colleagues' article (1) with interest. In 2016, the World Health Organization (WHO) endorsed the use of fractional-dose yellow fever vaccination subcutaneously in response to an acute vaccine shortage during a yellow fever outbreak. The rationale for this recommendation was that standard doses of WHO-prequalified yellow fever vaccines are highly potent, with average doses between 12 874 and 43 651 IU-far greater than WHO's recommended minimum of 1000 IU. Some countries have considered the use of fractional-dose vaccination outside of an emergency situation because of vaccine shortages (2) , but such use is not yet compliant with the International Health Regulations. Critical research questions remain, such as what is the duration of immunity with a single dose of the fractional-dose vaccine, the immunogenicity of yellow fever vaccine doses with a potency less than 1000 IU, and the safety and immunogenicity across different populations.
Roukens and colleagues' study (1) is an important step forward in our understanding of the use of fractional-dose yellow fever vaccines. The authors studied the 10-year dura-tion of immunogenicity of a one-fifth fractional dose administered intradermally. They showed that 40 healthy adults who received a 0.1-mL fractional dose intradermally 10 years ago had similar virus-neutralizing antibody responses to 35 persons who received the standard 0.5-mL dose subcutaneously 10 years ago (1). Their results were also similar to a recent study on the 10-year duration of subcutaneous administration of a standard dose (3) . Although these findings are encouraging and support the idea that long-term immunogenicity of fractional doses is similar to that of standard doses when administered intradermally, important policy questions remain.
First, Roukens and colleagues' study only investigated intradermal administration of fractional doses. However, the yellow fever vaccine is only licensed and prequalified by WHO to be given by subcutaneous or intramuscular routes. The authors contend that virus levels are equivalent when administered at the same dose by intradermal and subcutaneous routes, but immunogenicity typically differs with intradermal administration and a head-to-head comparison of intradermal versus subcutaneous administration on short-and long-term immunogenicity is needed to assess equivalence.
Second, the potency of the fractional doses used in Roukens and colleagues' study was always greater than 1000 IU; as such, their study does not address the knowledge gap on long-term immunogenicity for doses lower than the WHO minimum recommendation of 1000 IU. The primary study that informed the WHO recommendation to use fractional doses in 2016 was a dose-response trial investigating doses less than 1000 IU, with some as low as 31 IU (4). This dose deescalating study was done in 2009 in Brazil using a vaccine manufactured by Bio-Manguinhos. Doses as low as 587 IU showed similar humoral immunogenicity to the full dose of 27 476 IU when both were administered subcutaneously, whereas the 158-IU and 31-IU doses displayed lower immunogenicity. A recall study of the same participants done 8 years later showed that seropositivity was maintained in 85% of the participants and was similar across the different potencies (5) .
Finally, Roukens and colleagues' data were restricted to healthy adults and their findings cannot necessarily be extrapolated to other populations. The extent and duration of protection of fractional doses in such populations as children, pregnant women, and those with HIV and other comorbidities that may weaken vaccine responses are currently unknown. The first study on the one-fifth dose that included children as young as 2 years of age was done in the Democratic Republic of the Congo after the emergency rollout of fractional doses and, reassuringly, showed high seroconversion 1 month after subcutaneous administration (6). The results of a randomized controlled noninferiority trial comparing seroconversion after fractional-dose versus full-dose vaccination for each WHO-prequalified vaccine product (ClinicalTrials.gov: NCT02991495), including in such special populations as children and persons with HIV, are eagerly awaited.
Until these questions have been answered for each WHO-prequalified yellow fever vaccine product, fractional vaccination is not yet International Health Regulations compliant and should be used only in emergency situations during an acute vaccine shortage. If subcutaneous fractional-dose vaccination is shown to be equivalent to standard-dose vaccination in terms of long-term protection and safety, then the lower dose could become an antigen-sparing strategy of much broader utility. Diagnosis of Pulmonary Embolism During Pregnancy TO THE EDITOR: Righini and colleagues (1) conclude that a diagnostic strategy based on assessment of clinical probability, D-dimer testing, compression ultrasonography, and computed tomography pulmonary angiography can safely exclude pulmonary embolism (PE) in pregnant women. Our recent, larger study-Diagnosis of PE in Pregnancy (DiPEP)-challenges this conclusion.
Annelies Wilder-Smith, MD, PhD
The DiPEP study evaluated clinical probability scores (modified for pregnancy) and D-dimer assays in 181 pregnant or postpartum women with PE that was confirmed by imaging or autopsy and 259 pregnant or postpartum women in whom PE was excluded after imaging (2) . All the clinical probability scores had poor discriminant value for PE. Of note, the simplified revised Geneva score (used by Righini and colleagues) had an area under the receiver-operating characteristic curve of 0.579 (95% CI, 0.526 to 0.632). The sensitivity and specificity of D-dimer measurements were similarly poor. D-Dimer testing taken as part of routine care in 168 participants had a sensitivity of 88.4% (CI, 74.1% to 95.6%) and specificity of 8.8% (CI, 4.7% to 15.6%) using a conventional threshold and a sensitivity of 69.8% (CI, 53.7% to 82.3%) and specificity of 32.8% (CI, 24.8% to 41.9%) using a higher, pregnancy-specific threshold.
Our findings are compatible with those of Righini and colleagues. In their cohort, PE was excluded by clinical probability and D-dimer testing in only 46 participants. If clinical probability and D-dimer measurement provided no diagnostic value, we would expect approximately 3 of these 46 participants to have PE; this outcome is compatible with observing no events during 3-month follow-up despite no treatment. We thus believe that their study was underpowered to assess the usefulness of D-dimer testing and clinical probability in excluding PE in pregnancy.
Decision analysis modeling in the DiPEP study (3) also showed that scanning all women with suspected PE accrued more quality-adjusted life-years and incurred fewer costs than any selective strategy based on clinical probability and was therefore the dominant strategy. A threshold analysis showed that a clinical decision rule to select women for imaging would need to have sensitivity exceeding 97.5% to be costeffective compared with nonselective use of scanning.
The clinical and social consequences of missed PE are potentially catastrophic, whereas the cost savings and reduced radiation associated with avoiding 46 scans across 11 centers over 8 years are trivial. As such, we conclude that clinical probability scores and D-dimer assays have poor utility in diagnosing suspected PE in pregnancy and the puerperium period. Only imaging studies reliably exclude PE. TO THE EDITOR: We believe that Righini and colleagues' article (1) discussing a strategy for diagnosis of PE in pregnancy has serious ethical limitations. Their study was done in 11 large medical centers in Switzerland and France with access to magnetic resonance imaging. Magnetic resonance pulmonary angiography is an attractive new tool that avoids radiation exposure and does not use nephrotoxic contrast agents. We believe that their study should have examined the use of this test as the diagnostic tool.
The complications of computed tomography pulmonary angiography include the use of injected iodinated contrast (which has known renal complications and may cause allergic reactions) and exposure to ionizing radiation (which can be teratogenic and may cause cancer). A recent Cochrane systematic review on diagnosis of PE in pregnancy concluded that direct comparisons of diagnostic methods, including magnetic resonance imaging, are needed (2). Computed tomography and magnetic resonance imaging have a similar sensitivity and specificity for diagnosing PE (3). Computed tomography in pregnant women raises substantial concerns for exposure to both contrast and radiation. Furthermore, Righini and colleagues do not recommend placing a shield on the abdomen of the pregnant woman to decrease the exposure to radiation. Magnetic resonance pulmonary angiography can confidently diagnose PE, and facilities with this technology are available in developed European nations.
We also believe that 3-month follow-up is grossly inadequate for assessing the effects of radiation on both the mother and the fetus. This follow-up period was instituted only for the control group to ensure that a thromboembolic event did not occur; the patients who had radiation exposure had no follow-up.
The principles of good clinical practice state, "Before a trial is initiated, foreseeable risks and inconveniences should be weighed against the anticipated benefit for the individual trial subject and society. A trial should be initiated and continued only if the anticipated benefits justify the risks. The rights, safety, and well-being of the trial subjects are the most important considerations" (4). IN RESPONSE: Our trial is the first prospective management outcome study on PE in pregnant patients. In contrast, the DiPEP study was a retrospective analysis of 2 cohorts (one of women with suspected PE recruited in 11 centers and one of women with confirmed PE across the United Kingdom) and included pregnant and postpartum women. The DiPEP study used different D-dimer assays with different thresholds (1). It did not specify the timing of D-dimer measurement, but most women were already receiving anticoagulant therapy at the time of testing. Also, the final comparator to assess the diagnostic performance of this testing was the presence or absence of PE, which was based on clinical grounds in approximately 15% of patients. The inferences reported in the DiPEP study therefore have potentially important limitations.
We agree that our study does not provide a definitive conclusion on the safety of D-dimer testing during pregnancy given the wide CIs around the estimates of 3-month risk for venous thromboembolism. However, it is the first prospective management cohort study in which pretest probability assessment and D-dimer testing were used to exclude PE. Moreover, our results should be interpreted in the context of previous data on the use of D-dimer testing to exclude suspected venous thromboembolism in pregnancy (2) . In addition, we strongly believe that trying to avoid radiation during pregnancy-even if only in 1 in 10 patients-is important. The results of the Artemis study (Netherlands Trial Register: NTR5913) will soon be published and should provide further data on the use of D-dimer testing to exclude PE in pregnant patients.
We disagree with Drs. Malnick and Kikayon. Research on the performance of magnetic resonance imaging to diagnose PE is limited (3, 4) . A sensitivity of approximately 75% has been reported, which is not acceptable for a potentially fatal disease, such as PE (5) . No prospective management outcome studies have yet confirmed the safety of excluding PE on the basis of normal findings on magnetic resonance pulmonary angiography, particularly in pregnant women. As such, none of the available clinical practice guidelines supports its use to diagnose PE.
Reducing exposure to radiation for the mother and fetus is important. However, the consensus (which is supported by international recommendations) is that the risks of undiagnosed PE or inappropriate anticoagulation far outweigh any risk from diagnostic imaging in pregnant women. Definitively confirming or excluding PE by using validated diagnostic algorithms and tools is thus crucial. Until further evidence becomes available, we strongly recommend against use of magnetic resonance pulmonary angiography to diagnose PE in pregnant patients. More Evidence to Help Guide Decision Making About Aspirin for Primary Prevention TO THE EDITOR: Pignone and DeWalt's (1) endorsement of reducing aspirin use for primary cardiovascular prevention in a low-risk general population should have advised primary care practitioners about the unexpected increase in acute cardiac events after this therapy is discontinued (2) . The decrease in cardiovascular morbidity and mortality with low-dose aspirin in women at high risk for preterm preeclampsia in a placebo-controlled trial exemplifies the efficacy of such use in persons at above-average short-term risk (3). Aspirin use was associated with a 44% reduction in first acute myocardial infarctions in middle-aged men in a randomized controlled primary prevention trial (4). As such, it has been proposed for athletes with elevated coronary artery calcium scores to mitigate the transiently increased risk for cardiac arrest and sudden death due to coronary artery disease during marathons and triathlons in the United States since 2000 (5) . As a reliable and independent predictor of incident cardiac events, includ-ing death during middle age, such scores may identify ath
Marc Righini, MD
IN RESPONSE:
We did not intend to imply that the new evidence suggests that discontinuing aspirin therapy should be encouraged. Of note, we specifically differentiated the question of whether to initiate aspirin therapy (particularly in older adults) from whether to stop it. We believe that the newer evidence suggests caution when initiating this therapy in older adults but does not address whether to continue it in persons who tolerate it well. Those who are considering stopping aspirin therapy should be apprised of the risk associated with discontinuation (1).
The newer trials do not contradict the idea that aspirin reduces nonfatal myocardial infarction. A recent meta-analysis published after our commentary reinforces this finding (2) . Given the clear increased risk for bleeding with aspirin, using this therapy becomes more favorable as cardiovascular risk increases. We did not examine whether coronary artery calcium scoring is indicated to help better refine risk prediction to guide decisions about aspirin therapy; this subject has been examined when making decisions about statin use in other work and deserves to be studied for aspirin (3) . 
Michael Pignone, MD, MPH
IN RESPONSE:
We found that antibiotic prescribing in directto-consumer telemedicine is associated with shorter encounters. Dr. Llor and colleagues question the generalizability of this finding to the outpatient setting and note the high proportion of sinusitis diagnoses in our study relative to most outpatient settings. The genesis of our research question was anecdotal: Physicians in the outpatient setting often note that talking a patient out of an antibiotic takes longer than just prescribing one. Although we agree that there are features of telemedicine that distinguish it from outpatient care, why such factors would distort the relationship between antibiotic prescribing and visit length remains unclear. Two studies have shown that shorter encounters are associated with antibiotic receipt in outpatient care (1, 2) . Our study had the advantage of a large national sample and precise measurement of encounter length by the telemedicine system. As Dr. Llor and colleagues note, we were unable to adjust for illness acuity or whether the patient demanded antibiotics. However, antibiotics are generally prescribed for patients with more severe illness or comorbid complexity (3); both of these factors would be expected to extend visits, which makes our findings more striking.
We agree that the high proportion of sinusitis diagnoses probably represents overdiagnosis. Indeed, we recently showed that physicians with the highest overall antibiotic prescribing rates are those most likely to diagnose sinusitis (4). This type of coding bias has also been documented in outpatient care (3) . Nevertheless, the spectrum of disease seen in telemedicine may differ from that in primary care. Why this should affect the relationship between prescribing and visit length is unclear, because we adjusted for diagnosis, and patient expectations for antibiotics are the same in both settings.
Dr. Llor and colleagues suggest that telemedicine does not act as a substitute for urgent care because most patients seen in the telemedicine setting would not have sought care otherwise. Although we agree that telemedicine may induce demand among some persons, it is simply a more convenient alternative to outpatient or urgent care for many working adults. Only 15% of patients in our study stated that they would have done nothing if telemedicine had not been available. Given rapid uptake among younger urban adults (5) and expanded insurance coverage for telemedicine visits, virtual care will increasingly mirror that in brick-and-mortar settings. Physicians across the board face challenges in counseling patients about not needing antibiotics for respiratory tract infections. Their suspicion that doing so takes more time seems to be correct. Whether in telemedicine or outpatient care, interventions to promote antimicrobial stewardship should consider the physician time involved.
Why What You May Not Know About Fecal Immunochemical Testing Matters
TO THE EDITOR:
In his editorial endorsing fecal immunochemical testing (FIT), Allison (1) adopts the most optimistic perspective of the evidence to conclude that FIT has an effect similar to that of colonoscopy. However, a more conservative interpretation yields a different conclusion. Meta-analysis of 5 large randomized controlled trials with intention-to-screen analysis has shown that flexible sigmoidoscopy consistently prevented colorectal cancer (CRC) and reduced the risk for death (that is, all-cause mortality) despite examining only one half of the colon. These are landmark outcomes by themselves. However, regression analysis of these outcomes also shows a clear dose-response relation between preventing CRC and reducing death. Furthermore, it indicates that CRC prevention accounts for the entire mortality effect, implying that early diagnosis of CRC did not affect the risk for death. This finding correlates with the outcomes of 4 similar trials of fecal occult blood testing that showed that this intervention did not prevent CRC and was not even associated with a nonsignificant trend toward fewer deaths (relative risk, 1.001) (2, 3) . The outcomes of these 9 large, high-quality randomized controlled trials of colorectal screening thus do not lend credence to the supposition that early diagnosis of CRC extends life but rather indicate that death reduction is mostly dependent on preventing CRC, which in turn is dependent on detecting adenomatous polyps. Unfortunately, FIT performs poorly at adenoma detection, a fact explicitly acknowledged in Imperiale and associates' related review (4) .
A more conservative perspective of colorectal screening is that only flexible sigmoidoscopy has direct evidence showing CRC prevention and/or death reduction and that there is a clear and obvious rationale to expect colonoscopy to perform similarly or better. Similar randomized controlled trials conversely showed that fecal occult blood testing did not prevent CRC or reduce death. Moreover, current studies of FIT do not provide direct evidence or good rationale indicating that this intervention will do better in terms of these outcomes. The proposition that FIT will perform similarly to colonoscopy is based on the assumption that the major benefit of screening is early detection of CRC and that CRC prevention has negligible benefit. The clinical trial evidence contradicts this assumption.
From the perspective of the highest-quality studies and the outcomes that are most objective and important to patients, clinicians should continue to favor colonoscopy until direct evidence or solid rationale shows that FIT can prevent CRC and reduce death. IN RESPONSE: Dr. Swartz's statement that FIT performs poorly at adenoma detection has been expressed previously (1) . The assertion reveals a still-too-common misunderstanding of organized FIT-based screening programs. These programs do not rely on the sensitivity of a 1-time application of FIT (application sensitivity) but instead recommend and promote repeated annual testing (as is done in the United States). Only approximately 6% of all polyps become cancer, and the dwell time from benign polyp to cancer is slow: Annual FIT thus allows many opportunities to detect and remove those polyps most likely to become cancer.
This lack of knowledge about FIT has been used to declare colonoscopy the best and gold standard CRC screening test, a fact still unproven in randomized controlled trials. In 2008, the joint guideline of the U.S. Multi-Society Task Force on Colorectal Cancer promoted the ideas that fecal tests do not prevent cancer, prevention is the primary goal of CRC screening, and stool tests are less likely to prevent cancer than invasive ones (2) . Because evidence of the worthiness of FIT has grown (3), these beliefs fortunately have mostly disappeared. This shift happened partly as a result of changed messages from such groups as the National Colorectal Roundtable and American College of Physicians.
As of 2019, no U.S. CRC screening guideline recommends colonoscopy as the best or gold standard test or states that FIT is a poor test for detecting polyps. The U.S. Preventive Services Task Force does not call any of their recommended tests the "best." Furthermore, the 2017 U.S. Multi-Society Task Force on Colorectal Cancer recommends FIT as 1 of 2 firsttier screening methods for CRC, recognizing its ability to reduce both the incidence of and mortality from CRC (4). In 2018, Levin and associates (5) reported data showing that Kaiser Permanente's FIT-based organized CRC screening program rapidly increased screening participation to the target of 80% or higher set by national organizations. Screening rates were sustainable and associated with substantial decreases in CRC incidence and mortality within short time intervals, consistent with early detection and cancer prevention.
Almost all of the CRC screening programs in the world use population-based organized screening, and almost all have chosen 2-step screening with FIT as the first step. It is past the time for the United States to join the crowd.
